CAMBRIDGE, Mass., April 12, 2019 (GLOBE NEWSWIRE) — Biogen (Nasdaq: BIIB) today announced it will present new data illustrating the rapidly progressive nature of spinal muscular atrophy (SMA) in adults, adolescents and older children at the Muscular Dystrophy Association (MDA) Clinical and Scientific Conference in Orlando, Florida (April 13-17, 2019). Other Biogen presentations will highlight the benefits of pre-symptomatic treatment with data from the NURTURE study, part of the SPINRAZA® (nusinersen) global clinical trial program, and findings on the role of neurofilament as a potential biomarker for predicting motor function in SMA.
A therapy must be secured. If you must to paying for your own social treatment with your own financial means, then it’s a poker game. Out of pure desperation, many parents and patients do that.
Spinraza is still not available to all SMA Folks. Especially adults, teenagers over 18 years struggle so hard. Magnus 18 years old from Denmark with SMA type 1 has paid his own treatment for more than 1 year.
Now a monastery from Denmark has donated to Magnus, so that he can continue his therapy
Please consider a treatment with Spinraza must be a lifetime